Jingjing Zhu

List of Publications by Year
in descending order

12 papers	353 citations	1478505 6 h-index	1474206 9 g-index
12 all docs	12 docs citations	12 times ranked	725 citing authors

#	Article	IF	Citations
1	Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nature Communications, 2017, 8, 1404.	12.8	177
2	Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Cancer Immunology, Immunotherapy, 2019, 68, 835-847.	4.2	94
3	A Novel Magnetic Nanoparticle Drug Carrier for Enhanced Cancer Chemotherapy. PLoS ONE, 2012, 7, e40388.	2.5	32
4	Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochemical Journal, 2012, 448, 73-82.	3.7	26
5	Obesity and colorectal cancer risk: the role of oxidative stress. Gut, 2014, 63, 529-530.	12.1	8
6	Curcumin affects proprotein convertase activity: Elucidation of the molecular and subcellular mechanism. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1924-1935.	4.1	6
7	T Cellâ€“Mediated Targeted Delivery of Antiâ€“PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site. Cancer Immunology Research, 2022, 10, 713-727.	3.4	4
8	Is Curcumin for Monoclonal Gammopathy of Undetermined Significance without Risk? â€“ Letter. Clinical Cancer Research, 2010, 16, 2225-2225.	7.0	3
9	Polyphenols with indirect proprotein convertase inhibitory activity. International Journal of Oncology, 2013, 43, 947-955.	3.3	2
10	Abstract 1981: Interference of the polyphenolic compound curcumin with expression regulation of target genes of thePLAG1oncogenic transcription factor. , 2012, , .		1
11	Comment on: Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, doubleâ€blind placeboâ€controlled crossover 4g study and an openâ€label 8g extension study. American Journal of Hematology, 2012, 87, E80.	4.1	0
12	Abstract P025: Uncovering molecular actors of IDO-mediated T cell dysfunction with genome-wide CRISPR/Cas9 knockout screens. , 2022, , .		0